96 related articles for article (PubMed ID: 20632397)
1. Enzymatic stability, solution structure, and antiproliferative effect on prostate cancer cells of leuprolide and new gonadotropin-releasing hormone peptide analogs.
Pappa EV; Zompra AA; Spyranti Z; Diamantopoulou Z; Pairas G; Lamari FN; Katsoris P; Spyroulias GA; Cordopatis P
Biopolymers; 2011; 96(3):260-72. PubMed ID: 20632397
[TBL] [Abstract][Full Text] [Related]
2. Structural elucidation of Leuprolide and its analogues in solution: insight into their bioactive conformation.
Laimou DK; Katsara M; Matsoukas MT; Apostolopoulos V; Troganis AN; Tselios TV
Amino Acids; 2010 Nov; 39(5):1147-60. PubMed ID: 20354741
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a stable gonadotropin-releasing hormone analog in mice for the treatment of endocrine disorders and prostate cancer.
Katsila T; Balafas E; Liapakis G; Limonta P; Montagnani Marelli M; Gkountelias K; Tselios T; Kostomitsopoulos N; Matsoukas J; Tamvakopoulos C
J Pharmacol Exp Ther; 2011 Mar; 336(3):613-23. PubMed ID: 21106905
[TBL] [Abstract][Full Text] [Related]
4. Effect of GnRH analogs on the expression of TrkA and p75 neurotrophin receptors in primary cell cultures from human prostate adenocarcinoma.
Sánchez C; Clementi M; Benitez D; Contreras H; Huidobro C; Castellón E
Prostate; 2005 Nov; 65(3):195-202. PubMed ID: 15948150
[TBL] [Abstract][Full Text] [Related]
5. Peptides and antitumor activity. Development and investigation of some peptides with antitumor activity.
Teplán I
Acta Biol Hung; 2000; 51(1):1-29. PubMed ID: 10866357
[TBL] [Abstract][Full Text] [Related]
6. Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I.
Montagnani Marelli M; Moretti RM; Mai S; Procacci P; Limonta P
Int J Oncol; 2007 Jan; 30(1):261-71. PubMed ID: 17143537
[TBL] [Abstract][Full Text] [Related]
7. Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma.
Castellón E; Clementi M; Hitschfeld C; Sánchez C; Benítez D; Sáenz L; Contreras H; Huidobro C
Cancer Invest; 2006; 24(3):261-8. PubMed ID: 16809153
[TBL] [Abstract][Full Text] [Related]
8. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines.
Pályi I; Vincze B; Kálnay A; Turi G; Mezõ I; Teplán I; Seprõdi J; Pató J; Móra M
Cancer Detect Prev; 1996; 20(2):146-52. PubMed ID: 8706040
[TBL] [Abstract][Full Text] [Related]
9. Silencing of the GnRH type 1 receptor blocks the antiproliferative effect of the GnRH agonist, leuprolide, on the androgen-independent prostate cancer cell line DU145.
Ko YH; Ha YR; Kim JW; Kang SG; Jang HA; Kang SH; Park HS; Cheon J
J Int Med Res; 2011; 39(3):729-39. PubMed ID: 21819703
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis-related gene expression affected by a GnRH analogue without induction of programmed cell death in LNCaP cells.
Angelucci C; Iacopino F; Lama G; Capucci S; Zelano G; Boca M; Pistilli A; Sica G
Anticancer Res; 2004; 24(5A):2729-38. PubMed ID: 15517879
[TBL] [Abstract][Full Text] [Related]
11. Evidence for hormone-responsive cleavage of gonadotropin-releasing hormone by the plasma membrane of ovarian cancer cells.
Imai A; Iida K; Furui T; Tamaya T
Int J Oncol; 2002 May; 20(5):987-92. PubMed ID: 11956594
[TBL] [Abstract][Full Text] [Related]
12. Gonadotropin-releasing hormone agonist blocks anxiogenic-like and depressant-like effect of corticotrophin-releasing hormone in mice.
Umathe SN; Bhutada PS; Jain NS; Shukla NR; Mundhada YR; Dixit PV
Neuropeptides; 2008 Aug; 42(4):399-410. PubMed ID: 18533256
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity studies of lGnRH-III through rational amino acid substitution and NMR conformational studies.
Pappa EV; Zompra AA; Diamantopoulou Z; Spyranti Z; Pairas G; Lamari FN; Katsoris P; Spyroulias GA; Cordopatis P
Biopolymers; 2012; 98(6):525-34. PubMed ID: 23203758
[TBL] [Abstract][Full Text] [Related]
14. Leuprorelin acetate affects ERK1/2 activity in prostate cancer cells.
Iacopino F; Lama G; Angelucci C; Sica G
Int J Oncol; 2006 Jul; 29(1):237-47. PubMed ID: 16773205
[TBL] [Abstract][Full Text] [Related]
15. Cell growth effects of leuprolide on cultured endometrioma cells.
Levine D; Kaufman L; Cuenca VG; Badawy SZ
J Reprod Med; 2007 Jul; 52(7):581-4. PubMed ID: 17847754
[TBL] [Abstract][Full Text] [Related]
16. Effects of GnRH analogs on six ovarian cancer cell lines in culture.
Connor JP; Buller RE; Conn PM
Gynecol Oncol; 1994 Jul; 54(1):80-6. PubMed ID: 8020844
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic uses of gonadotropin-releasing hormone analogs.
Andreyko JL; Marshall LA; Dumesic DA; Jaffe RB
Obstet Gynecol Surv; 1987 Jan; 42(1):1-21. PubMed ID: 3543765
[TBL] [Abstract][Full Text] [Related]
18. Leuprorelin acetate affects adhesion molecule expression in human prostate cancer cells.
Angelucci C; Lama G; Iacopino F; Sica G
Int J Oncol; 2011 Jun; 38(6):1501-9. PubMed ID: 21479359
[TBL] [Abstract][Full Text] [Related]
19. Gonadotropin-releasing hormone and ovarian cancer: a functional and mechanistic overview.
So WK; Cheng JC; Poon SL; Leung PC
FEBS J; 2008 Nov; 275(22):5496-511. PubMed ID: 18959739
[TBL] [Abstract][Full Text] [Related]
20. Anticancer activity of a new gonadotropin releasing hormone analogue.
Saleh-Abady MM; Naderi-Manesh H; Alizadeh A; Shamsipour F; Balalaie S; Arabanian A
Biopolymers; 2010; 94(3):292-7. PubMed ID: 19908246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
